Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Nicola Tilt"'
Autor:
Vivian P. Bykerk, Peter Nash, David Nicholls, Yoshiya Tanaka, Kevin Winthrop, Christina Popova, Nicola Tilt, Derek Haaland
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 3, Pp 693-706 (2023)
Abstract Introduction There is a paucity of data on how patient characteristics may affect the long-term durability of certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA). This study therefore aimed to investigate CZP durability and r
Externí odkaz:
https://doaj.org/article/9b9eee02ab004b669a8f54f870bb39c3
Autor:
Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt, Mark Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 1, Pp 315-328 (2022)
Abstract Introduction Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumour necrosis factor biologic. Safety and efficacy data for CZP over 3 years have been previously reported. We report 3-year quality of life (QoL) outcomes for patients t
Externí odkaz:
https://doaj.org/article/dada9e3da46542c3926158754f9215ab
Autor:
Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt, Mark Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 6, Pp 1389-1390 (2023)
Externí odkaz:
https://doaj.org/article/96ef422959844e0b94a00b022614f0c3
Autor:
Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux‐Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui
Publikováno v:
ACR Open Rheumatology, Vol 3, Iss 8, Pp 501-511 (2021)
Objective To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. Methods Safety data were pooled across 34 CZP clinical trials i
Externí odkaz:
https://doaj.org/article/bc65d43bb8c340d5b0b51aece614f660
Autor:
Yoshiya Tanaka, Tsutomu Takeuchi, Derek Haaland, Stephen Hall, Nevsun Inanc, Zhanguo Li, Ricardo M. Xavier, Carlos Cara, Nicola Tilt, Peter C. Taylor
Aim:Certolizumab pegol (CZP), an Fc-free, PEGylated tumor necrosis factor inhibitor (TNFi), has shown rapid and sustained reduction in signs and symptoms of rheumatoid arthritis (RA). Elevated rheumatoid factor (RF) level has been associated with RA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51bf878cb8853a854a6537a13928b893
https://doi.org/10.1111/1756-185x.14699
https://doi.org/10.1111/1756-185x.14699
Autor:
Kathryn Bailey, Richard Bruggraber, Boglarka Szegvari, Kerri Sunderland, Irina Mountian, Nicola Tilt
Publikováno v:
Advances in Therapy
Introduction The CIMZIA® AutoClicks® pre-filled pen (CZP PFP) was developed to overcome barriers to self-injection, by improving self-injection confidence, reducing fear associated with needle use, and supporting patients with impaired dexterity. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac1174d1bb25a2e840470b48d826d649
https://doi.org/10.1007/s12325-020-01257-6
https://doi.org/10.1007/s12325-020-01257-6
Autor:
April Armstrong, Sandra McBride, Lynda Spelman, Pablo Fernández-Peñas, Phoebe Rich, George Martin, Nicola Tilt, Jose M. Lopez Pinto, Christina Popova, Scarlett Hellot
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB175
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e8bd4b04f25f2ecc7b7bbd24f8b1363
https://doi.org/10.1016/j.jaad.2022.06.731
https://doi.org/10.1016/j.jaad.2022.06.731
Autor:
Yoshinori Umezawa, Shigetoshi Sano, Nicola Tilt, Akimichi Morita, Hidemi Nakagawa, Naoki Hoshii, Shinichi Imafuku, Shinya Sakurai, Akihiko Asahina, Yayoi Tada
Publikováno v:
Dermatology and Therapy
Introduction Certolizumab pegol (CZP), an Fc-free, PEGylated anti-tumour necrosis factor biologic, dosed at 400 mg every 2 weeks (Q2W) and 200 mg Q2W over 16 weeks, resulted in improvements in Japanese patients with moderate to severe plaque psoriasi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75047bf6507f73b1bf900a28c4b5cb7c
https://pubmed.ncbi.nlm.nih.gov/33886085
https://pubmed.ncbi.nlm.nih.gov/33886085
Autor:
Christina Popova, Nicola Tilt, Andrew Blauvelt, Kevin L. Winthrop, Cécile Gaujoux-Viala, Boulos Haraoui, Tore K Kvien, Xavier Mariette, Jeffrey R. Curtis, Vivian P. Bykerk
Publikováno v:
ACR Open Rheumatology
ACR Open Rheumatology, Wiley, 2021, 3 (8), pp.501-511. ⟨10.1002/acr2.11259⟩
ACR Open Rheumatology, Vol 3, Iss 8, Pp 501-511 (2021)
ACR Open Rheumatology, Wiley, 2021, 3 (8), pp.501-511. ⟨10.1002/acr2.11259⟩
ACR Open Rheumatology, Vol 3, Iss 8, Pp 501-511 (2021)
International audience; Objective: To investigate the impact of baseline and time-varying factors on the risk of serious adverse events (SAEs) in patients during long-term certolizumab pegol (CZP) treatment.Methods: Safety data were pooled across 34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11958758a0bbc9d1ccb2664ec5412f9e
https://hal.archives-ouvertes.fr/hal-03633756
https://hal.archives-ouvertes.fr/hal-03633756
Autor:
Carlos Cara, Ricardo Machado Xavier, Carine Saadoun, Yoshiya Tanaka, Nevsun Inanc, Tsutomu Takeuchi, Zhanguo Li, Nicola Tilt
Publikováno v:
Anais do Congresso Brasileiro de Reumatologia 2020.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dcb7e5194ff4293a26a5bcc6329073e
https://doi.org/10.47660/cbr.2020.17164
https://doi.org/10.47660/cbr.2020.17164